FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris, Inc. (OTCBB: VYHN), today released findings of a market demand and pricing study for its product, LidoSite, the active drug delivery patch that delivers local anesthesia for use prior to venipuncture and routine blood draws. LidoSite is the first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration (FDA).
